Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.

ABSTRACT:

Background

Real-world data on chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone plus prednisone are limited, largely deriving from small retrospective studies.

Methods

ABitude is an Italian, observational, prospective, multicenter study of mCRPC patients receiving abiraterone plus prednisone in clinical practice. Chemotherapy-naïve mCRPC patients were consecutively enrolled at abiraterone start (February 2016 to June 2017) and are being followed for 3 years, with evaluation approximately every 6 months. Several clinical and patients reported outcomes were examined.

Results

In this second interim analysis, among 481 enrolled patients, 453 were evaluable for analyses. At baseline, the median age was 77 year

SUBMITTER: Procopio G 

PROVIDER: S-EPMC7604981 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature